Evidence map›Paper›PMID 23968241›Full record

ReviewJournal of neurotrauma2014

Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup.

Ramon Diaz-Arrastia, Patrick M Kochanek, Peter Bergold, Kimbra Kenney, Christine E Marx, Col Jamie B Grimes, L T C Yince Loh, L T C Gina E Adam, Devon Oskvig, Kenneth C Curley and 1 more

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of neurotrauma, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06163833 (MATRIx), which is not on this map. Cited by 135 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 5 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06163833 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

MATRIx: MesenchymAl Stromal Cells for Traumatic bRain Injury

TypeinterventionalSponsorFondazione IRCCS San Gerardo dei TintoriRan2023 to 2026Enrolled78ConditionsTraumatic Brain Injury With Loss of ConsciousnessArmsMesenchymal stromal cell low dosage-80*10^6 cells, Mesenchymal stromal cell low dosage-160*10^6 cells, Placebo-storage solution
3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 5 syntheses or guidelines pooled it, 262 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Neuroprotective therapy after traumatic brain injury: does the window for treatment extend for months?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Ramon Diaz-Arrastia1 Department of Neurology, Uniformed Services University of the Health Sciences , Bethesda, Maryland.
Patrick M Kochanek
Peter Bergold
Kimbra Kenney
Christine E Marx
Col Jamie B Grimes
L T C Yince Loh
L T C Gina E Adam
Devon Oskvig
Kenneth C Curley
Wanda Salzer
United States Army Medical Research and Development Command · USUniformed Services University of the Health Sciences · USDefense & Veterans Center for Integrative Pain Management · USDuke University Hospital · USMadigan Army Medical Center · USSUNY Downstate Health Sciences University · USUniversity of Pittsburgh · US

Funding

Polynitroxylated Pegylated Hemoglobin for Traumatic Brian Injury ResuscitationU44NS070324 · NINDS · SYNZYME TECHNOLOGY, INC. · PI HSIA, CARLETON · 2011 to 2016
$1.6M
Sildenafil for the treatment of cerebrovascular dysfunction in chronic TBIZIANS003138 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI DIAZ-ARRASTIA, RAMON · 2013 to 2016
$36k
NINDS NIH HHS 1U44NS070324PHS HHS R01070512
6 · The paper itself

Abstract

Despite substantial investments by government, philanthropic, and commercial sources over the past several decades, traumatic brain injury (TBI) remains an unmet medical need and a major source of disability and mortality in both developed and developing societies. The U.S. Department of Defense neurotrauma research portfolio contains more than 500 research projects funded at more than $700 million and is aimed at developing interventions that mitigate the effects of trauma to the nervous system and lead to improved quality of life outcomes. A key area of this portfolio focuses on the need for effective pharmacological approaches for treating patients with TBI and its associated symptoms. The Neurotrauma Pharmacology Workgroup was established by the U.S. Army Medical Research and Materiel Command (USAMRMC) with the overarching goal of providing a strategic research plan for developing pharmacological treatments that improve clinical outcomes after TBI. To inform this plan, the Workgroup (a) assessed the current state of the science and ongoing research and (b) identified research gaps to inform future development of research priorities for the neurotrauma research portfolio. The Workgroup identified the six most critical research priority areas in the field of pharmacological treatment for persons with TBI. The priority areas represent parallel efforts needed to advance clinical care; each requires independent effort and sufficient investment. These priority areas will help the USAMRMC and other funding agencies strategically guide their research portfolios to ensure the development of effective pharmacological approaches for treating patients with TBI.

Indexed as

Biomedical ResearchBrain InjuriesHumansNeuropharmacologyUnited StatesUnited States Department of Defense

Identifiers

PMID23968241
PMCPMC3900003
OpenAlexW2316762748

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.